A44 - Metastatic breast cancer outcome in real life: a single institution experience. Preliminary results

Abstract

Background: Many treatments are available for metastatic breast cancer (MBC) and the choice should be based on specific characteristics such as hormone receptor and human epidermal growth factor receptor 2 (HER2), tumor involvement and prior treatments. Gene profiling studies have underlined the heterogeneity of BC and have distinguished subtypes based on molecular characteristics. In daily clinical practice patients (pts) are classified based on immunohistochemistry. The present study correlates progression free survival (PFS), overall survival (OS) and survival postprogression (SPP) of MBC pts to biological characteristics. Hereby we present data on PFS and OS.Material and methods: We retrieved medical records of 346 MBC pts treated at our institution. 325 were analysed (15 pts never started therapy, 1 received RT only and 5 not already evaluated). We collected data on primary and advanced disease, and defined the subgroups according to S. Gallen criteria: Luminal A (LA), Luminal B (LB), HER2 positive and triple negative (TN).Results: Median age at diagnosis was 58 y (range 26-87), median age at diagnosis of MBC was 63 y (28-87), F/M: 320/5, most common metastatic site: bone 180 pts (55.4%), soft tissues 167 pts (51.4%), liver 71 pts (21.8%), lung 70 pts (21.5%) and CNS 16 pts (4.9%). 97 pts (29.8%) presented de novo MBC. Median time to MBC from initial diagnosis of BC was 45.6 m (3.2-281). Immunophenotypes were: LA 28 (8.6%), LB 155 (47.7%), HER2 52 (16%), TN 24 (7.4%) missing 66 (20.3%). 181 pts (55.7%) received neo/adjuvant chemotherapy, 159 pts (48.9 %) received adjuvant endocrine therapy. Pts were exposed to a median of 3 (1-16) lines of therapy. All pts were exposed to 1st line, 225 (69.2%) to 2nd, 155 (47.7%) to 3rd, 108 (33.2%) to 4th, 78 (24%) received 5 or more lines. Median PFS at 1st line was 11,1+ months (m) (0.2-153.8), 6.5+ m (0.4-85.4) at 2nd, 4.7+ m (0.2-50.6) at 3rd, and 5 m (0.4-92.5+) at 4th. Median OS was 27.3+ m (0.3-199.2). LA, LB, HER2 and TN pts received a median of 2.5 (1-11), 2 (1-16), 3 (1-13) and 2 (1-6) lines respectively. Median OS in LA, LB, HER2 and TN was 36.3+ m (2.2-96.1), 26.6+ m (0.3-193.1), 25.6+ m (1.1-193.5) and 12.1 m (2.2-94.3+) respectively.Conclusions: Our results are in line with other similar reports. Interestingly the median PFS decreases from the 1st to the 3rd line of therapy, but, does not between 3rd and 4th line. Data on SPP will be presented. Background: Many treatments are available for metastatic breast cancer (MBC) and the choice should be based on specific characteristics such as hormone receptor and human epidermal growth factor receptor 2 (HER2), tumor involvement and prior treatments. Gene profiling studies have underlined the heterogeneity of BC and have distinguished subtypes based on molecular characteristics. In daily clinical practice patients (pts) are classified based on immunohistochemistry. The present study correlates progression free survival (PFS), overall survival (OS) and survival postprogression (SPP) of MBC pts to biological characteristics. Hereby we present data on PFS and OS. Material and methods: We retrieved medical records of 346 MBC pts treated at our institution. 325 were analysed (15 pts never started therapy, 1 received RT only and 5 not already evaluated). We collected data on primary and advanced disease, and defined the subgroups according to S. Gallen criteria: Luminal A (LA), Luminal B (LB), HER2 positive and triple negative (TN). Results: Median age at diagnosis was 58 y (range 26-87), median age at diagnosis of MBC was 63 y (28-87), F/M: 320/5, most common metastatic site: bone 180 pts (55.4%), soft tissues 167 pts (51.4%), liver 71 pts (21.8%), lung 70 pts (21.5%) and CNS 16 pts (4.9%). 97 pts (29.8%) presented de novo MBC. Median time to MBC from initial diagnosis of BC was 45.6 m (3.2-281). Immunophenotypes were: LA 28 (8.6%), LB 155 (47.7%), HER2 52 (16%), TN 24 (7.4%) missing 66 (20.3%). 181 pts (55.7%) received neo/adjuvant chemotherapy, 159 pts (48.9 %) received adjuvant endocrine therapy. Pts were exposed to a median of 3 (1-16) lines of therapy. All pts were exposed to 1st line, 225 (69.2%) to 2nd, 155 (47.7%) to 3rd, 108 (33.2%) to 4th, 78 (24%) received 5 or more lines. Median PFS at 1st line was 11,1+ months (m) (0.2-153.8), 6.5+ m (0.4-85.4) at 2nd, 4.7+ m (0.2-50.6) at 3rd, and 5 m (0.4-92.5+) at 4th. Median OS was 27.3+ m (0.3-199.2). LA, LB, HER2 and TN pts received a median of 2.5 (1-11), 2 (1-16), 3 (1-13) and 2 (1-6) lines respectively. Median OS in LA, LB, HER2 and TN was 36.3+ m (2.2-96.1), 26.6+ m (0.3-193.1), 25.6+ m (1.1-193.5) and 12.1 m (2.2-94.3+) respectively. Conclusions: Our results are in line with other similar reports. Interestingly the median PFS decreases from the 1st to the 3rd line of therapy, but, does not between 3rd and 4th line. Data on SPP will be presented.